A new trading day began on Monday, with Prelude Therapeutics Inc (NASDAQ: PRLD) stock price up 13.45% from the previous day of trading, before settling in for the closing price of $1.71. PRLD’s price has ranged from $0.61 to $4.22 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -21.61%. Meanwhile, its annual earnings per share averaged 20.44%. With a float of $39.89 million, this company’s outstanding shares have now reached $43.75 million.
Prelude Therapeutics Inc (PRLD) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 47.32%, while institutional ownership is 21.51%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.37 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.44% per share during the next fiscal year.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Here are Prelude Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Looking closely at Prelude Therapeutics Inc (NASDAQ: PRLD), its last 5-days average volume was 0.5 million, which is a drop from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 90.34%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 34.29%, which indicates a significant decrease from 94.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1583 in the past 14 days, which was lower than the 0.1837 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5553, while its 200-day Moving Average is $1.0754. However, in the short run, Prelude Therapeutics Inc’s stock first resistance to watch stands at $2.0433. Second resistance stands at $2.1465. The third major resistance level sits at $2.3132. If the price goes on to break the first support level at $1.7734, it is likely to go to the next support level at $1.6067. Now, if the price goes above the second support level, the third support stands at $1.5035.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
With a market capitalization of 146.88 million, the company has a total of 62,865K Shares Outstanding. Currently, annual sales are 7,000 K while annual income is -127,170 K. The company’s previous quarter sales were 6,500 K while its latest quarter income was -19,730 K.
